Metastases to Bone
Conditions
Keywords
Blood Transfusion, Neoplasm Metastasis, Bone
Brief summary
This study assesses the safety and efficacy of TXA for patients treated for pathological femur fractures using modular prosthetics.
Detailed description
Tranexamic acid is an efficacious medication for curtailing blood loss, haemoglobin drop, and the requirement for transfusions. Additionally, it is a secure medication, even when administered to oncology patients receiving reduction haemarthroplasty for pathological femoral fractures.
Interventions
DRUGTranexamic acid injection
Tranexamic acid were administered at a dose of 1.0 g during the induction of anaesthesia and immediately after surgery.
Sponsors
Piotr Biega
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patological fracture * Arthroplasty using a modular prosthesis.
Exclusion criteria
* threatened fracture * intraoperative blood transfusion * fracture fixation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants who require a blood transfusion. | During Hospitalization (up to day 10) | Need of blood transfusion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Estimeted blood lost after surgery. | During Hospitalization (up to day 3) | Gross total blood loss was estimated utilizing the formula PBV × (Hctpre- Hctpost)/Hcta |
| Number of participants with embolic complication. | During Hospitalization (up to day 10) | Yes or No |
Countries
Poland
Outcome results
None listed